Denmark and Texas Medical Center Announce BioBridge Partnership
TMC’s third such international partnership unites world’s largest medical city with Denmark – one of Europe’s leading life science nations – with the goal of driving the next generation of health and medical advancements
HOUSTON, TX – (OCTOBER 2, 2019) – Texas Medical Center– the world’s largest medical city – and the Danish Ministry of Health on behalf of the Kingdom of Denmark today announced a collaborative and multi-faceted BioBridge partnership that will focus on two main areas: Innovation and Research & Education.
“In March of this year, Texas Medical Center proudly hosted Her Royal Highness Crown Princess Mary of Denmark. Following that occation The Consultate General and Texas Medical center began the dialogue in order to begin building the foundation for the BioBridge partnership being announced today,” commented William McKeon, President & CEO of TMC. He added, “Now, TMC and the Kingdom of Denmark officially align each entity’s respective startup ecosystems and will further accelerate the global pace of clinical research by fostering collaboration between academic researchers within the Texas Medical Center and at Denmark’s esteemed institutions.”
The TMC / Denmark BioBridge is designed to bolster innovation and initially focus on a number of sub-areas including: Digital / Tele Health – in order to improve patient health and care experience through digital platforms; Medical Device – focused on the improvement of patient outcomes through new innovative medical devices; and Operations – in order to better streamline hospital service and operational models across facilities in both TMC and Denmark.
“Denmark welcomes the significant potential of this trans-Atlantic BioBridge partnership with Texas Medical Center and its vast array of world class resources,” noted Magnus Heunicke, Denmark’s Minister of Health and Senior Citizens. He added, “Through this BioBridge, we build the foundation for the successful exchange of ideas, technologies, pratices and research that is at the center of breakthrough innovation and better healthcare globally.”
The second tenet of the agreement between TMC and Denmark focuses on Research & Education. The two prongs of this area of interest outlined in the BioBridge partnership call for emphasis on Clinical Research by identifying current and future instances of clinical trial activity for collaboration as well as the identification of opportunities surrounding Precision & Personalized Medicine.
In a ceremony held on Tuesday, October 1 in Copenhagen, representatives from TMC and Denmark jointly announced the BioBridge partnership, outlined the goals of the program and its structure, and conducted breakout sessions focused on Research and Innovation.
As a member of the new medical device cohort of TMCx, Texas Medical Center’s startup accelerator housed within its sprawling TMC Innovation Institute campus, Danish-based company Neurescue is already reaping the benefits of the BioBridge collaboration. Neurescue, based in Copenhagen specifically, has developed a computer-aided aortic occlusion catheter to help save the lives of patients in the emergency care setting. The company will develop its product and learn from TMC leaders and experts over the course of the next four months of the TMCx program.
The TMC / Denmark BioBridge is the culmination of extensive conversations between Texas Medical Center and the Kingdom of Denmark, including the aforementioned visit by HRH Queen Crown Princess Mary to Texas Medical Center in the spring of 2019.
In conclusion, McKeon remarked, “When HRH Crown Princess Mary visited the Texas Medical Center, she recognized the role of emerging technology in the advancement in health care in both of our nations. Here in Copenhagen today at this momentous occasion, I am thrilled to formalize the BioBridge partnership that stands as tangible proof that we can always learn from our friends and colleagues around the world in our collective pursuit to advance care.”
About Texas Medical Center
Texas Medical Center (TMC)—the largest medical city in the world—is at the forefront of advancing life sciences. Home to the brightest minds in medicine, TMC nurtures cross-institutional collaboration, creativity, and innovation among its 106,000-plus employees. With a campus of more than 50 million square feet, TMC annually hosts 10 million patients, performs over 180,000 surgeries, conducts over 750,000 ER visits, performs close to 14,000 heart surgeries, and delivers over 25,000 babies. Beyond patient care, TMC is pushing the boundaries of clinical research across its extensive network of partner institutions on a daily basis, pioneering effective health policy solutions to address the complex health care issues of today, and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu.
About the Kingdom of Denmark as a Life Science Nation
Denmark has emerged as a world leader in life sciences and health. Thecountry is at the top of industries such as drug development, biotechnology and medical technology.Denmark has a strong life science cluster of high quality throughout the value chain. Measured by market size per capita, the medical device industry in Denmark is the second largest in Europe and measured in drugs per capita, Denmark has the largest commercial drug development pipeline in Europe.
Widely known for quality patient data and one of the best data collection systems in existence, Denmark is a global leader in the deployment and use of Health IT systems, and ranks among the top in the EU-28 EU member states on the Digital Economy and Society Index.
Life science exports account for 17% of Danish national exports and expected to double by 2025.
The TMC delegation visit was organized in collaboration with Healthcare DENMARK, an organization that has a national mandate to promote Danish healthcare excellence.
Her Royal Highness Mary, Crown Princess of Denmark is patron of Healthcare DENMARK.
To learn more about Danish healthcare, visit healthcaredenmark.dk.
Mark Sullivan / Jonathan Babin